SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ -- Immusoft of CA, a clinical stage, engineered B cell company, today announced a historic achievement: the safe and well-tolerated re-dosing of a patient with ...
The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001 ...
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has ...
Hosted on MSN
Neuraptive Therapeutics Enrolls First Patient in Phase 3 Trial for NTX-001 Nerve Repair Therapy
CHESTERBROOK, PA — Neuraptive Therapeutics, Inc. announced the enrollment of the first patient in its phase 3 clinical trial evaluating NTX-001, an investigational therapy designed to improve outcomes ...
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (MSCL:CA) (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to ...
Doron Therapeutics Announces First Patients Dosed in Phase 3 Study of MOTYS (PTP-001) for the Treatment of Osteoarthritis of the Knee — Global Trial to Assess Injectable Biologic Therapy for Pain ...
Hosted on MSN
Adicet Bio doses first patient in ADI-001 trial
Adicet Bio (ACET) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA. Take advantage of TipRanks Premium at 50% off! Unlock ...
Doron Therapeutics, a clinical-stage biotechnology company developing novel biologics for musculoskeletal diseases, today announced that the initial patients have been dosed in its Phase 3 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback